Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease
Mansour A Alghamdi,1,2 Laith AL-Eitan,3 Rami Alkhatib,3 Ahmad Al-Assi,4 Ayah Almasri,3 Hanan Aljamal,3 Hatem Aman,3 Rame Khasawneh5 1Department of Anatomy, College of Medicine, King Khalid University, Abha, 61421, Saudi Arabia; 2Genomics and Personalized Medicine Unit, College of Medicine, King Khal...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-03-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/variants-in-cdhr3-cacnac1-and-lta-genes-predisposing-sensitivity-and-r-peer-reviewed-article-IJGM |
| _version_ | 1818859339724619776 |
|---|---|
| author | Alghamdi MA AL-Eitan L Alkhatib R Al-Assi A Almasri A Aljamal H Aman H Khasawneh R |
| author_facet | Alghamdi MA AL-Eitan L Alkhatib R Al-Assi A Almasri A Aljamal H Aman H Khasawneh R |
| author_sort | Alghamdi MA |
| collection | DOAJ |
| description | Mansour A Alghamdi,1,2 Laith AL-Eitan,3 Rami Alkhatib,3 Ahmad Al-Assi,4 Ayah Almasri,3 Hanan Aljamal,3 Hatem Aman,3 Rame Khasawneh5 1Department of Anatomy, College of Medicine, King Khalid University, Abha, 61421, Saudi Arabia; 2Genomics and Personalized Medicine Unit, College of Medicine, King Khalid University, Abha, 61421, Saudi Arabia; 3Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan; 4Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan; 5Department of Hematopathology, King Hussein Medical Center (KHMC), Royal Medical Services (RMS), Amman, 11118, JordanCorrespondence: Laith AL-EitanDepartment of Biotechnology & Genetic Engineering/Faculty of Science and Arts, Jordan University of Science and Technology, P.O.Box 3030, Irbid, 22110, JordanTel +962-2-7201000 ext 23464Email lneitan@just.edu.joIntroduction: Warfarin has been in use for more than 60 years; however, it has serious side effects including major bleeding. The high interpatient variability in the required dose impacts the sensitivity and responsiveness to warfarin in different patients. This study aims to assess the influence of CDHR3, CACNAC1, and LTA gene polymorphisms on the variability of warfarin dose requirements and susceptibility to coronary heart disease in the Jordanian population.Methods: This study was conducted in the anti-coagulation clinic in Queen Alia Heart Institute in Amman, with 212 patients in total. Three SNPs were genotyped within CDHR3 (rs10270308), CACNAC1 (rs216013), and LTA (rs1041981) genes.Results: Our findings revealed that patients with LTA polymorphism are more prone to warfarin sensitivity than others. Furthermore, carriers of the LTA polymorphism needed a lower initial dose of warfarin and are associated with less variation in doses required to achieve target INR.Conclusion: The current study could help in understanding the role of genetic variability in warfarin dosing and matching patients to different treatment options. Clinical applications of these findings for warfarin treatment may also contribute to improving the efficacy and safety of warfarin treatment in Jordanian patients with cardiovascular disease.Keywords: warfarin, pharmacogenetics, single nucleotide polymorphisms, INR, stroke |
| first_indexed | 2024-12-19T09:10:37Z |
| format | Article |
| id | doaj.art-75287d713b064a008b12b272d231e280 |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-12-19T09:10:37Z |
| publishDate | 2021-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-75287d713b064a008b12b272d231e2802022-12-21T20:28:12ZengDove Medical PressInternational Journal of General Medicine1178-70742021-03-01Volume 141093110063409Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular DiseaseAlghamdi MAAL-Eitan LAlkhatib RAl-Assi AAlmasri AAljamal HAman HKhasawneh RMansour A Alghamdi,1,2 Laith AL-Eitan,3 Rami Alkhatib,3 Ahmad Al-Assi,4 Ayah Almasri,3 Hanan Aljamal,3 Hatem Aman,3 Rame Khasawneh5 1Department of Anatomy, College of Medicine, King Khalid University, Abha, 61421, Saudi Arabia; 2Genomics and Personalized Medicine Unit, College of Medicine, King Khalid University, Abha, 61421, Saudi Arabia; 3Department of Biotechnology and Genetic Engineering, Jordan University of Science and Technology, Irbid, 22110, Jordan; 4Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan; 5Department of Hematopathology, King Hussein Medical Center (KHMC), Royal Medical Services (RMS), Amman, 11118, JordanCorrespondence: Laith AL-EitanDepartment of Biotechnology & Genetic Engineering/Faculty of Science and Arts, Jordan University of Science and Technology, P.O.Box 3030, Irbid, 22110, JordanTel +962-2-7201000 ext 23464Email lneitan@just.edu.joIntroduction: Warfarin has been in use for more than 60 years; however, it has serious side effects including major bleeding. The high interpatient variability in the required dose impacts the sensitivity and responsiveness to warfarin in different patients. This study aims to assess the influence of CDHR3, CACNAC1, and LTA gene polymorphisms on the variability of warfarin dose requirements and susceptibility to coronary heart disease in the Jordanian population.Methods: This study was conducted in the anti-coagulation clinic in Queen Alia Heart Institute in Amman, with 212 patients in total. Three SNPs were genotyped within CDHR3 (rs10270308), CACNAC1 (rs216013), and LTA (rs1041981) genes.Results: Our findings revealed that patients with LTA polymorphism are more prone to warfarin sensitivity than others. Furthermore, carriers of the LTA polymorphism needed a lower initial dose of warfarin and are associated with less variation in doses required to achieve target INR.Conclusion: The current study could help in understanding the role of genetic variability in warfarin dosing and matching patients to different treatment options. Clinical applications of these findings for warfarin treatment may also contribute to improving the efficacy and safety of warfarin treatment in Jordanian patients with cardiovascular disease.Keywords: warfarin, pharmacogenetics, single nucleotide polymorphisms, INR, strokehttps://www.dovepress.com/variants-in-cdhr3-cacnac1-and-lta-genes-predisposing-sensitivity-and-r-peer-reviewed-article-IJGMwarfarinpharmacogeneticssingle nucleotide polymorphismsinrstroke. |
| spellingShingle | Alghamdi MA AL-Eitan L Alkhatib R Al-Assi A Almasri A Aljamal H Aman H Khasawneh R Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease International Journal of General Medicine warfarin pharmacogenetics single nucleotide polymorphisms inr stroke. |
| title | Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease |
| title_full | Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease |
| title_fullStr | Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease |
| title_full_unstemmed | Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease |
| title_short | Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease |
| title_sort | variants in cdhr3 cacnac1 and lta genes predisposing sensitivity and response to warfarin in patients with cardiovascular disease |
| topic | warfarin pharmacogenetics single nucleotide polymorphisms inr stroke. |
| url | https://www.dovepress.com/variants-in-cdhr3-cacnac1-and-lta-genes-predisposing-sensitivity-and-r-peer-reviewed-article-IJGM |
| work_keys_str_mv | AT alghamdima variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT aleitanl variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT alkhatibr variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT alassia variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT almasria variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT aljamalh variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT amanh variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease AT khasawnehr variantsincdhr3cacnac1andltagenespredisposingsensitivityandresponsetowarfarininpatientswithcardiovasculardisease |